ResMed (RMD) Tops Q3 Views
More News related to RMD
- Notable Analyst Rating Changes 11/06: GE, CBS, HD/LOW, M Upgrade; ESLR, RMD, SUN Downgrade
- Morgan Stanley Downgrades ResMed (RMD) to Equalweight
- Jefferies & Co Downgrades ResMed (RMD) to Hold
- ResMed (RMD) Tops Q3 Views
- ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
ResMed Inc. (NYSE: RMD) reports Q3 EPS of $0.57, ex-items, 7 cents better than the analyst estimate of $0.50. Revenue for the quarter was $247 million, which compares to the estimate of $239.50 million.
Related Categories
EarningsStocks Mentioned
-0.42Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
